These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 20642748)

  • 21. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy.
    Martinez-Rodriguez JE; Seppi K; Cardozo A; Iranzo A; Stampfer-Kountchev M; Wenning G; Tolosa E; Högl B; Santamaria J; Poewe W;
    Mov Disord; 2007 Sep; 22(12):1822-4. PubMed ID: 17659646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normal cerebrospinal fluid levels of hypocretin-1 (orexin A) in patients with fibromyalgia syndrome.
    Taiwo OB; Russell IJ; Mignot E; Lin L; Michalek JE; Haynes W; Xiao Y; Zeitzer JM; Larson AA
    Sleep Med; 2007 Apr; 8(3):260-5. PubMed ID: 17369087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nacrolepsy manifesting initially as cataplexy and sleep paralysis: usefulness of CSF hypocretin-1 examination for early diagnosis].
    Kobayashi Y; Miyamoto M; Miyamoto T; Yamazaki K; Hirata K; Kanbayashi T; Shimizu T
    Rinsho Shinkeigaku; 2002 Mar; 42(3):233-6. PubMed ID: 12474294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleep polygraphic study of children and adolescents with narcolepsy/cataplexy.
    Ferri R; Franceschini C; Zucconi M; Drago V; Manconi M; Vandi S; Poli F; Bruni O; Plazzi G
    Dev Neuropsychol; 2009; 34(5):523-38. PubMed ID: 20183716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Narcolepsy with cataplexy].
    Dauvilliers Y; Arnulf I
    Rev Neurol (Paris); 2008; 164(8-9):634-45. PubMed ID: 18805301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Excessive daytime sleepiness and low CSF orexin-A/hypocretin-I levels in a patient with probable progressive supranuclear palsy].
    Hattori Y; Hattori T; Mukai E; Mori H; Mizuno Y; Kayukawa Y; Okada T; Kanbayashi T
    No To Shinkei; 2003 Dec; 55(12):1053-6. PubMed ID: 14870576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants.
    Poryazova R; Benninger D; Waldvogel D; Bassetti CL
    Eur Neurol; 2010; 63(3):129-35. PubMed ID: 20090346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?
    Baumann C; Ferini-Strambi L; Waldvogel D; Werth E; Bassetti CL
    J Neurol; 2005 Feb; 252(2):139-45. PubMed ID: 15729517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of cataplexy and HLADR1501 in narcolepsy.
    Inoue Y; Honda Y; Takahashi Y; Nanba K; Ishii A; Saitou K
    Psychiatry Clin Neurosci; 2002 Jun; 56(3):279-80. PubMed ID: 12047595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.
    Baumann CR; Dauvilliers Y; Mignot E; Bassetti CL
    Eur Neurol; 2004; 52(2):73-6. PubMed ID: 15256827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia].
    Martínez-Rodríguez JE; Iranzo A; Casamitjana R; Graus F; Santamaria J
    Med Clin (Barc); 2007 Mar; 128(10):361-4. PubMed ID: 17386240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.
    Aldrich MS; Chervin RD; Malow BA
    Sleep; 1997 Aug; 20(8):620-9. PubMed ID: 9351129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid eye movement sleep disturbances in Huntington disease.
    Arnulf I; Nielsen J; Lohmann E; Schiefer J; Wild E; Jennum P; Konofal E; Walker M; Oudiette D; Tabrizi S; Durr A
    Arch Neurol; 2008 Apr; 65(4):482-8. PubMed ID: 18413470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and mechanisms of neck myoclonus in narcolepsy.
    Xu W; Zhang X; Zhang B; Lu S; Huang W; Xu J; Liu Y; Zhao W; Yan Z; Yu Y; Qiu S; Wu B; Tang J
    Sleep Med; 2024 Nov; 123():22-28. PubMed ID: 39226673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
    Mieda M; Willie JT; Hara J; Sinton CM; Sakurai T; Yanagisawa M
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4649-54. PubMed ID: 15070772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Narcolepsy in the older adult: epidemiology, diagnosis and management.
    Chakravorty SS; Rye DB
    Drugs Aging; 2003; 20(5):361-76. PubMed ID: 12696996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy.
    Nevsimalova S; Prihodova I; Kemlink D; Lin L; Mignot E
    Sleep Med; 2007 Nov; 8(7-8):784-6. PubMed ID: 17569582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.
    Andlauer O; Moore H; Jouhier L; Drake C; Peppard PE; Han F; Hong SC; Poli F; Plazzi G; O'Hara R; Haffen E; Roth T; Young T; Mignot E
    JAMA Neurol; 2013 Jul; 70(7):891-902. PubMed ID: 23649748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.